Oncology Nurse Advisor has partnered with leading medical publishers to present Publishers Alliance, a selection of oncology-focused articles from a number of clinically relevant research journals. 


Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

[Cancer Management and Research] In this study, researchers explored the potential of andrographolide and topotecan, separately and together, in the in vitro treatment of the U937 acute myeloid leukemic cell line.

Are Ovarian Cancer Stem Cells the Target for Innovative Immunotherapy?

Are Ovarian Cancer Stem Cells the Target for Innovative Immunotherapy?

[OncoTargets and Therapy] In a review of cancer stem cells (CSCs)/ovarian cancer stem cells (OCSCs), researchers discuss the implications of immunotherapy development based on studying cancer evolution by CSCs, and targeting OCSC surface markers to develop CAR-T immunotherapy.

Response to Rapamycin Analogs but not PD-1 Inhibitors in PTEN-mutated Metastatic Non-small Cell Lung Cancer With High Tumor Mutational Burden

Response to Rapamycin Analogs but not PD-1 Inhibitors in PTEN-mutated Metastatic Non-small Cell Lung Cancer With High Tumor Mutational Burden

[Lung Cancer: Targets and Therapy] This case study demonstrates that genomic profiling may still benefit patients who fail checkpoint inhibitor therapy despite having high tumor mutational burden and PD-L1 positivity.

Multiple Treatment Modalities for Brain Metastasis in Patients With EGFR-mutant Non-small Cell Lung Cancer

Multiple Treatment Modalities for Brain Metastasis in Patients With EGFR-mutant Non-small Cell Lung Cancer

[OncoTargets and Therapy] Management of brain metastases in patients with EGFR-mutant NSCLC is controversial. In this study, researchers find combination and sequential treatment with EGFR-TKIs, chemotherapy, and radiotherapy is beneficial.

Role and Inhibition of GLI1 Protein in Cancer

Role and Inhibition of GLI1 Protein in Cancer

[Lung Cancer: Targets and Therapy] Italian researchers report on the role of GLI1 in the development of lung cancer, and review its potential as an effective therapy for lung cancer.

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

[Cancer Management and Research] A review of marginal zone lymphomas, a common and varied group of hematologic malignancies, and their treatment, with a focus on the Bruton's tyrosine kinase ibrutinib.

Emerging Treatment Options for BRAF-mutant Colorectal Cancer

Emerging Treatment Options for BRAF-mutant Colorectal Cancer

[Gastrointestinal Cancer: Targets and Therapy] This review presents the most up-to-date molecular, clinical, and therapeutic data, including an overview of a current phase 3 study assessing the efficacy of simultaneous BRAF, EGFR, and MEK inhibition among patients with BRAFV600E-mutant CRC.

Clinicopathological Features and Prognosis in Elderly Gastric Cancer Patients: A Retrospective Cohort Study

Clinicopathological Features and Prognosis in Elderly Gastric Cancer Patients: A Retrospective Cohort Study

[OncoTargets and Therapy] A retrospective study assessed patients with gastric cancer, identifying disease characteristics more prevalent in elderly patients and the effect on prognosis for these patients.

Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer

Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer

[Breast Cancer: Targets and Therapy] Researchers present a review of the LHRH agonist triptorelin and the use of this agent to induce chemical castration in estrogen-sensitive breast cancer tumors in younger women.

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

[Cancer Management and Research] This report presents an assessment of the relationship of Bax/Bcl-2 expression and the clinical response of patients with AML treated with cytarabine plus daunorubicin, and their potential as biomarkers to predict chemotherapeutic outcomes.

Our Publishing Partners


ARE YOU A PUBLISHER LOOKING TO JOIN OUR PUBLISHERS ALLIANCE TEAM? FIND OUT MORE!


Your research articles may be of interest
to our wide-ranging audience of oncology professionals.


CLICK HERE to e-mail the Editor for more information!

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs